NCT06213311View on ClinicalTrials.gov

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions

B Cell Lymphoma

Interventions

DRUG

Glofitamab

Given by IV

DRUG

Obinutuzumab

Given by IV

DRUG

Axi-cel

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Kite, A Gilead Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER